TNFerade Receives FDA Fast Track Designation for Treatment of Pancreatic Cancer

Nov 11, 2008 - GenVec, Inc. announced today that TNFerade has been granted Fast Track product designation by the U.S. FDA for its proposed use in the treatment of locally advanced pancreatic cancer.

The details can be read here.